Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots: Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseases As per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience. Konrad believes…

BySaurabh ChaubeyApril 4, 2025

NEWS

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Shots: Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 deal As per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US…

ByRidhi RastogiApril 3, 2025

NEWS

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Shots: Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete…

ByRidhi RastogiApril 2, 2025

EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Vikram Mohan

Vikram Mohan will be joining the upcoming Pharma 2025 event as a panelist with the Topic “Content’s Industrial Revolution”. Vikram believes that with a paradigm shift from the traditional approach to creating, approving, reviewing, and deploying content in the evolving biopharma industry, there’s room for generative AI to act as an assistant to make the…

BySaurabh ChaubeyApril 2, 2025

NEWS

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Shots: Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platform Furthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disorders Upon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and…

ByRidhi RastogiApril 1, 2025

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…

ByRidhi RastogiApril 1, 2025

NEWS

Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides

Shots: Ionis has granted Sobi global exclusive rights of olezarsen excl. the US, Canada & China to treat familial chylomicronemia syndrome (FCS) & severely elevated triglycerides; Ionis to independently market Olezarsen in the US, whereas Theratechnologies holds the rights in Canada As per the deal, Ionis will get an upfront, with potential milestone payments &…

ByRidhi RastogiMarch 27, 2025

NEWS

Bayer Enters Global License Agreement with Suzhou Puhe BioPharma for its PRMT5 Inhibitor

Shots: Bayer & Suzhou Puhe BioPharma have entered into a global license agreement for Puhe BioPharma’s PRMT5 inhibitor to treat MTAP-deleted tumors As per the deal, Bayer will obtain rights to develop, manufacture & commercialize MTA-cooperative PRMT5 inhibitor globally; financial terms remain undisclosed Bayer to develop the asset under development name BAY 3713372, with first…

ByRidhi RastogiMarch 27, 2025

NEWS

Merck Partners with Jiangsu Hengrui Pharmaceuticals for HRS-5346, Expanding its Cardio-Metabolic Portfolio

Shots: Merck has entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346 As per the deal, Merck has obtained exclusive rights to develop, manufacture & commercialize HRS-5346 globally excl. Greater China region in exchange for $200M upfront & ~$1.77B in development, regulatory & commercial milestones, along with net sales-based royalties; closing expected…

ByRidhi RastogiMarch 25, 2025

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Reuters Pharma 2025: Pre-Conference Talks Featuring Vikram Mohan

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

PharmaShots’ Key Highlights of First Quarter 2025

Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides

Bayer Enters Global License Agreement with Suzhou Puhe BioPharma for its PRMT5 Inhibitor

Merck Partners with Jiangsu Hengrui Pharmaceuticals for HRS-5346, Expanding its Cardio-Metabolic Portfolio

Contact US

FOLLOW US